Drug
SHR-1701 clinical trials
Also written SHR-1701 and Retlirafusp alfa.
- studies test it
- 50
- open now
- 33
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the SHR-1701 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2026 (24)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 24 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 43
- Phase 3
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 36
Jiangsu HengRui Medicine Co., Ltd. (10) · Fudan University (5) · Tianjin Medical University Cancer Institute and Hospital (3) · Tang-Du Hospital (3) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · Harbin Medical University (2) · Henan Cancer Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)
Often tested with
Tested in the same studies.
Apatinib (8) · Famitinib (7) · Zeprumetostat (6) · Paclitaxel (5) · Albumin-Bound Paclitaxel (4) · Trastuzumab rezetecan (4) · Adebrelimab (4) · Carboplatin (3)
Studies
Open first, then newest update. How each study uses SHR-1701 is read from its arms, and is right about nine times in ten.
Testing it · 50
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Retlirafusp alfa
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as Retlirafusp alfa
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Retlirafusp alfa
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingPhase 2Henan Cancer HospitalNCT07817654Written as Trastuzumab Rezetecan+Retlirafusp alfa
- Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07814859Written as Retlirafusp alfa Injection
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07802288Written as Trastuzumab Rezetecan + Retlirafusp alfa + CAPOX
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDACNot yet recruitingPhase 1/2West China HospitalNCT07802184Written as SHR-1701
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07773363Written as Retlirafusp Alfa
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingPhase 2Tan LijieNCT07770672Written as Retlirafusp Alfa Plus Chemotherapy
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingPhase 2Harbin Medical UniversityNCT07752550Written as Retlirafusp alfa+Nab-paclitaxel:
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07749859Written as Retlirafusp alfa Injection, apatinib
- Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tang-Du HospitalNCT07709767Written as Retlirafusp Alfa
- Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07689851Written as SHR-1701
- Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver MetastasesNot yet recruitingPhase 3Peking UniversityNCT07677293Written as Retlirafusp alfa Injection
- Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCCNot yet recruitingPhase 2Tang-Du HospitalNCT07618910Written as Retlirafusp alfa
- Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07610629Written as Retlirafusp alfa + Apatinib + Nab-paclitaxel
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07567326Written as Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy
- Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)Not yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07550920Written as Drug: Retlirafusp alfa
- SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After ImmunotherapyNot yet recruitingPhase 2Zhigang LiNCT07524374Written as SHR-1701+ liposomal irinotecan (II)
- Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07517653Written as SHR-1701
See all 50 studies that test SHR-1701 →
Given in every arm · 7 — SHR-1701 is usual care beside what is tested
- Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLMRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07728019Written as Retlirafusp alfa Injection
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as SHR1701
- SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT07384234Written as SHR-1701
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07464756Written as SHR-1701
- SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07619911Written as SHR-1701 consolidation therapy
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07102901Written as SHR-1701 Injection
- SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04282070Written as SHR-1701